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Purpose: Symptomatic epilepsy is initiated by a brain insult, but most people suffering 
brain insults do not go on to develop epilepsy, indicating that some people are genetically 
predisposed to epilepsy after such insults. Genome wide association study (GWAS) is an 
effective way to find genes that contribute to diseases. The most significant SNP in a 
recent GWAS of symptomatic epilepsy in the Chinese population was rs2292096 [G] 
(p=1.0×10-8, OR=0.63), in the CAMSAP1L1 gene, also known as CAMSAP2. We chose 
to study this SNP as well as another SNP associated with epilepsy in the same GWAS, 
rs13021324 [C] (p=5.8×10-5, OR=0.73), which is in the epilepsy candidate gene ERBB4. 
CAMSAP1L1 encodes a cytoskeletal protein; however, it is not yet known to have any 
neurologically-specific function. ERBB4, a schizophrenia-susceptibility gene, has been 
reported to be mutated in a case of early myoclonic encephalopathy. We hypothesize that 
these two genes affect the predisposition of people to develop symptomatic epilepsy, and 
that the above SNPs influence gene expression or function. The objectives of this study 
are to elucidate some functions of CAMSAP1L1 and to explore whether the expression of 
the two genes will be affected by different genotypes.  
 
Methods: One CAMSAP1L1 SNP (rs2292096) and one ERBB4 SNP (rs13021324) were 
genotyped in epilepsy patients. RNA and homogenates were prepared from frozen 
hippocampus and temporal lobe tissue from epilepsy patients. CAMSAP1L1 and ERBB4 
RNA and protein levels were measured by real-time PCR and western blotting with 
reference to the housekeeping gene GAPDH, and expression levels were compared 
among genotypes of the above SNPs. We performed immunohistochemistry in paraffin-
embedded sections to compare CAMSAP1L1 protein levels between epilepsy and control 
subjects in hippocampus and temporal lobe. In addition, we used human SH-SY5Y 
neuroblastoma cells to examine CAMSAP1L1 localization and function, performing 
double immunofluorescence for CAMSAP1L1 and tubulin and measuring the effect of 






Results: In analysis of rs2292096 (CAMSAP1L1) in the temporal lobe, patients with the 
GG genotype showed higher expression of RNA (p=0.024), but not of protein (p=0.57). 
Immunohistochemistry showed a tendency toward lower expression of CAMSAP1L1 in 
epilepsy patients than in control subjects (p=0.059) in hippocampus but not in temporal 
lobe (p=0.12). Expression analysis of rs13021324 demonstrated non-significant 
tendencies toward higher expression of ErbB4 with C allele than the T allele for RNA 
and protein in hippocampus and temporal lobe. Double immunofluorescence showed 
CAMSAP1L1 expression on neurites, partially overlapping with β-tubulin. CAMSAP1L1 
siRNA transfection of SH-SY5Y cells treated with or without retinoic acid reduced the 
CAMSAP1L1 protein level nearly 60% and stimulated neurite outgrowth, as measured by 
outgrowths, processes and branches compared with the control siRNA group. 
 
Conclusion: The association of CAMSAP1L1 and ERBB4 SNPs with epilepsy is likely 
due to linkage disequilibrium with SNPs that affect functions or levels of CAMSAP1L1 
or ErbB4. Our data suggest that the rs2292096 GG genotype, which reduces risk of 
symptomatic epilepsy, tends to increase expression of CAMSAP1L1, but more subjects 
are needed to confirm this result. CAMSAP1L1 represses neurite outgrowth. A tendency 
toward higher expression of ErbB4 with the C allele is consistent with the GWAS finding 














癲癇的 GWAS 報導了一個在 1q32.1 的 CAMSAP1L1 基因 (也叫做 CAMSAP2) 上最
顯著的單核苷酸多態性 rs2292096 [G] （p=1.0×10-8，OR=0.63）。除了這個
























小（p=0.12）。 在 rs13021324（ERBB4）在 RNA 關聯表達分析中，攜帶等位基因
C 的患者的表達有高於 T 等位基因的一些趨勢, 但是不是很明顯。雙螢光試驗中，
我們看到 CAMSAP1L1 在神經突的表達，它與β-微管蛋白有部分的表達重疊，在
CAMSAP1L1 轉染實驗中，近 60％的基因被抑制，在 0μM 和 25μM RA 分化的
SH-SY5Y 細胞中，CAMSAP1L1 的 siRNA 引起的基因沉默顯著增強了神經突以及
分支的生長。 
 
結論：在 GWAS 中發現的 CAMSAP1L1 基因上 SNP 的 顯著型 p 值表明，SNP 和癲
癇之間的遺傳性關聯可能是由於特定 SNP 標記的單體型的蛋白質表達水平和功能
所決定的。我們的數據表明，在 SNP rs2292096 中，GG 基因型的人倾向于有較高
的表達，但需要更多的實驗來證實這一結果。CAMSAP1L1 會抑制神經突生長。對
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Chapter One Introduction 
    
1.1 Introduction to epilepsy  
1.1.1 Epilepsy types and epidemiology 
 
Epilepsy affects about 1% of the population all over the world1. Nearly 90% of epilepsy 
patients are in developing countries. Epilepsy becomes more common in older people2. It 
is characterized by unprovoked seizures. Epileptic seizures usually result from abnormal 
or excessive hypersynchronous neuronal activities in the brain 3 . Normally, no 
precipitating factors could be seen before seizures occur. Epilepsy syndromes are divided 
into the following three types: idiopathic, symptomatic and cryptogenic. Idiopathic 
epilepsy is common in children; examples include generalized epilepsy with febrile 
seizures plus (GEFS+), childhood absence epilepsy (CAE) and juvenile absence epilepsy 
(JAE). Symptomatic epilepsy is usually initiated by a brain insult such as injury, infection 
or brain tumors, with seizures developing some time later. Cryptogenic epilepsy 
resembles symptomatic epilepsy, but without a detectable brain lesion.   
 
Epilepsy can also be classified into types based on the localization of the seizures. Partial 
seizures, also known as focal seizures, only happen in certain locations in the brain. Focal 
seizures are divided into simple focal seizures and complex focal seizures. Patients with 
simple focal seizures usually have some unpleasant feelings such as sadness, joy or anger; 
however, they will remain conscious. On the contrary, in complex focal seizures, patients 
usually lose their consciousness, accompanied by strange movements such as blinks, 
smiles, or twitches. Some may even have sensations that a seizure will be coming.  
 
Generalized epilepsy is less common than partial epilepsy. In generalized epilepsy, 
usually both sides of the brain are damaged. There are many different kinds of 
generalized seizures. People with absence seizures appear to be staring at some places or 
jerking. Patients with tonic seizures experience stiffening of muscles of the body, usually 
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in the back, leg and arms. Clonic seizures cause repeated jerking of the muscles. Atonic 
seizures lead to loss of muscle tone. Myoclonic seizures cause jerking or twitching of the 
upper body. Focal and generalized seizures are not distinguished very clearly, and there is 
not a strict boundary between these two types of seizures. Sometimes, focal seizures can 
also develop into generalized seizures4.   
 
Common pathologies of epilepsy include hippocampal sclerosis (HS), focal cortical 
dysplasia (FCD), malformations of cortical development, and some tumors such as 
astrocytomas and dysembryoplastic neuroepithelial tumor (DNT) 5 . In hippocampal 
sclerosis, which occurs in nearly 70% of patients who undergo surgery for drug-resistant 
seizures, the morphology and function of neuronal circuits in the hippocampus or other 
brain regions are often altered, thus leading to an epileptic network6. Other pathologies, 
like malformations of cortical development or focal cortical dysplasia, also account for 
some types of epilepsy in children and adults. 
 
The incidence of epilepsy patients is 40-70 per 100,000 in industrialized countries and 
100-190 per 100,000 in resource-poor countries7. In developed countries, standardized 
mortality ratios range from 1.6 to 3.0 in all epilepsy patients and 2.2 to 6.5 in 
symptomatic epilepsy8. The death rate is even higher in patients with more frequent 
seizures. Epilepsy could also lead to some social problems in some countries, such as loss 
of employment, education or independence. Its impact on quality of life is greater than 
some other neurological disorders, and numerous factors in epilepsy, such as fear of 
seizures, depression, or poor self-esteem, could contribute to this. The suicide rate is also 
higher in epilepsy patients than in the general population9. Attention-deficit/hyperactivity 
disorder (ADHD) is about 3-5 times more prevalent among children with epilepsy than 
among children in the general population10. Children's behavioral, learning, and social 
development are significantly influenced by ADHD. 
 




In newly diagnosed epilepsy patients, some could become seizure-free after antiepileptic 
drug (AED) treatment or even without treatment. About two thirds of patients eventually 
achieve remission. However, nearly 30% of epilepsy patients have recurrent seizures and 
do not gain remission after drug treatment 11 . According to the International League 
Against Epilepsy (ILAE), patients can be defined as drug-resistant after the failure of 
adequate trials of two tolerated and appropriately chosen and used AED schedules 
(whether as monotherapy or in combination) to achieve sustained seizure freedom12 . 
Drug resistance also depends on epilepsy syndromes, with the most common type, 
symptomatic generalized epilepsy (SGE), comprising a majority of drug-resistant patients. 
As many as 75% of mesial temporal lobe epilepsy patients are considered to be drug-
resistant. The mechanism of drug-resistant epilepsy is still unclear; the main hypotheses 
include the target hypothesis and the multidrug-transporter hypothesis 13 . The target 
hypothesis claims that changes of the targets upon which AEDs act, such as ion-channel 
or neurotransmitter receptors, will lead to seizures. The multidrug-transporter hypothesis 
states that some AEDs are substrates of transporters, such as P-glycoprotein (Pgp), in the 
blood brain barrier (BBB), and the overexpression of some transporters will pump out 
AEDs so that they never reach the target. For example, the transporter which is studied 
most, Pgp, can transport many AEDs, such as phenytoin, phenobarbital, and gabapentin. 
Some AEDs are also substrates of other transporters, such as multidrug-resistant-
associated proteins (MRPs)14. However, epilepsy is a complex disorder; it is possible that 
multiple mechanisms play roles in drug resistance.   
 
1.1.3 Treatment for epilepsy 
         
Epilepsy is usually controlled, but not cured completely. The principle of anticonvulsant 
use is seizure freedom and minimal side effects. Normally, medication is the first choice 
to control and prevent seizures. More than 20 AEDs approved by the US Food and Drug 
Administration (FDA) are used in the clinic in the US, and the number of AEDs is still 
increasing. Other drugs, such as diazepam (Valium, Diastat) and lorazepam (Ativan), are 
also used to prevent active seizures or interrupt a seizure flurry. To demonstrate drug 
effectiveness, the FDA usually requires that at least 50% improvement is achieved in 
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50% of the patients in the treatment group. The particular AEDs prescribed usually 
depend on the epilepsy type since some AEDs may work better for certain seizure types.  
 
The UK National Institute for Health and Clinical Excellence (NICE) recommends that 
patients with newly diagnosed epilepsy try one AED at a time first. This is called 
monotherapy. If one AED can not prevent seizures well, patients may try a second line 
drug, either added to the first drug (polytherapy) or by itself. When patients change AEDs, 
drug-drug interactions and side effects must be taken into consideration. If seizures still 
occur after the two trials of AEDs, a neurologist must check a patient’s diagnosis before 
trying a third AED, or a patient may consider other treatments. The starting dose is 
usually low and is then increased according to requirements of individual patients. Such 
individual therapeutic concentration could produce a better effect on individuals and 
prevent unnecessary side effects. Some patients may achieve seizure freedom after AED 
treatment for a short time; nevertheless, some may need long-term treatment. A sudden 
discontinuation of AEDs may cause seizure recurrence, thus referral to a neurologist is a 
must when patients meet problems with medication. AEDs may be withdrawn gradually 
after a seizure-free period of two or more years. 
 
Surgery is necessary for patients with seizures that are difficult to control. It can remove 
epileptogenic areas such as tumors or arteriovenous malformations from the brain. The 
goal of surgery is to totally control the epilepsy 15 , although medication is still 
indispensable for treatment16. First, physicians must confirm the diagnosis of epilepsy to 
make sure the seizures arise from epilepsy. Neurological examination methods include 
routine electroencephalography (EEG), long-term video-EEG monitoring, 
neuropsychological evaluation, and neuroimaging such as MRI, single photon emission 
computed tomography (SPECT), and positron emission tomography (PET). A number of 
papers have reported the successful application of surgery. Jeha et al reported that 53% of 
371 patients become seizure free after anterior temporal lobe surgery17. Park CK et al 
reported one epilepsy study on children in Korea; among 30 children, 87% were 
considered as surgical successes in that they all showed an improvement18. A number of 
studies focused on relapses after surgery. This is a common phenomenon in epilepsy 
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patients, although the basis is still unclear. Some research pointed out that the probability 
of relapse is higher in patients who were seizure free for a long time than for a short 
time19, 20. 
 
Vagus nerve stimulation (VNS) is another treatment method, but it is controversial due to 
the greater concern over complications compared with surgery, as well as due to some 
findings that VNS can not achieve a high level of efficacy21, 22. Other devices using 
electrical stimulation are still being investigated, including the responsive 
neurostimulation system (RNS) and deep brain stimulation (DBS). The ketogenic diet 
(high-fat, low-carbohydrate) is also an effective way to treat refractory pediatric 
epilepsy23. It is mainly applied in children with refractory epilepsy. The ketogenic diet is 
gradually being replaced by surgery. 
 
1.2 Genetics of epilepsy 
1.2.1 Genetic mechanism underlying epilepsy 
 
Over the past decade, there has been rapid development in understanding the genetic 
factors involved in epilepsy. Genetic factors can lead to abnormal episodic 
hyperexcitability of neuron networks through various mechanisms. 
 
Idiopathic epilepsy is often thought to be caused at least partly by genetic factors because 
there is usually a family history of disease, and the seizures often occur in childhood or 
adolescence. Some families with epilepsy show a mendelian pattern of inheritance, which 
means that a single gene mutation causes disease. In these disorders, like GEFS+, SMEI, 
and benign neonatal convulsions, a single gene mutation may lead to the loss or change 
of protein function or to altered gene expression. Usually, a single gene mutation will 
initiate a cascade of epileptogenesis.  
 
Most of the monogenic idiopathic epilepsy syndromes follow an autosomal dominant 
inheritance pattern, and however, the penetrance of these mutations is less than 100%, 
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suggesting that other genes or environmental factors also contribute to the phenotype24,25. 
Other modes of monogenic inheritance like X-chromosomal, mitochondrial and complex 
inheritance also exist; however, most of the idiopathic epilepsy syndromes do not follow 
a monogenic inheritance pattern. In most cases, mutations in a group of genes will 
interact to determine the epilepsy inheritance pattern. Such inheritance patterns are called 
oligogenic or polygenic. GEFS+ exhibits several different inheritance patterns. 
Sometimes, there is one highly penetrant mutation in one gene that manifests major gene 
effect on phenotype. The mutation impact can be counterbalanced by alternative 
pathways if they exist, and this effect can be further modified by epigenetic factors, 
environmental factors and the genetic background of the patients26.  
 
Idiopathic epilepsies are often thought of as channelopathies because most of the 
mutations are in ion channel genes or their subunits. Ion channels are responsible for 
neurotransmitter release and for the excitability and communication of neurons. They 
also control the flow direction and the type of ions which pass through their gates. 
Normally, a tuned balance of excitatory and inhibitory input can maintain the normal 
function of the cortex. Any disturbance of this balance could lead to hyperexcitability and 
seizures. Undoubtedly, ion channels play a significant role in neuron-related disorders.  
 
Ion channels involved in epilepsy could be divided into two classes, voltage-gated and 
ligand-gated. Voltage-gated ion channels, including sodium, calcium, and potassium 
channels, often open and close in response to membrane potential. Ligand-gated ion 
channels are mainly involved in synaptic transmission. They act in response to a chemical 
messenger (ligand) binding to the extracellular domain of the receptor protein. 
Conformational changes after this binding result in the opening of the gate, after which 
ions flux across the membrane. The cation-permeable "nicotinic" acetylcholine receptor 
and the anion-permeable γ-aminobutyric acid-gated GABAA receptor are examples of 
this class27. 
 
Mutations of these channels or receptors can cause different types of idiopathic 
epilepsy28. Table 1.1 lists some genes involved in epilepsy29- 42.  
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Table 1.1 Some of the genes in which mutations have been found to cause epilepsy   
Gene description Gene  Epilepsy syndrome 













Sodium β-subunit SCN1B 
Sodium α-subunit SCN2A BFNIS3 
Chloride channel CLCN2 IGE 
GABAA receptors GABRG2/GABRA1 GEFS+/IGE 
Unknown  protein with a G-protein 
component interaction domain 
LGI1 ADLTE 
G-protein coupled receptors MASS1/VLGR1 FS 
Calcium homeostasis  EFHC1 EJM1 
GABA A-type subunit GABRA1 EJM5 
Calcium channel subunit CACNB4 EJM6 
GABA subunit GABRD EJM7 
Involved in synaptic vesicle release STXBP1 Ohtahara/EIEE syndrome 
Homeobox gene ARX 
Polyglucosan metabolism EPM2A/EPM2B(NHLRC1) Lafora disease 
Cysteine protease inhibition CSTB Unverricht–Lundborg disease 
Respiratory chain MTTK/MTTL1 MERRF 
Lipidoses PPT Infantile NCL 
Protease CLN2 Late infantile NCL 
Protease CLN3 Juvenile NCL 
Protease CLN5 Late infantile NCL, Finnish 
variant 
Protease CLN6 Late infantile NCL, Indian variant 
Protease CLN8 Northern epilepsy 




ADLTE, autosomal dominant lateral temporal lobe epilepsy; ADNFLE, autosomal dominant nocturnal 
frontal lobe epilepsy; BFNC, benign familial neonatal convulsions; FS, febrile seizures; GEFS+, 
generalized epilepsy with febrile seizures plus; IGE, idiopathic generalized epilepsies; MERRF, myoclonic 
epilepsy with ragged red fibres; NCL, neuronal ceroid lipofuscinosis; BFNIS, benign familial neonatal-
infantile seizures; SMEI, severe myoclonic epilepsy of infancy (Dravet syndrome); EJM, epilepsy, juvenile 
myoclonic; ADLTEAF, autosomal dominant lateral temporal epilepsy with auditory features; EFMR, 
epilepsy and mental retardation limited to females; EIEE, early infantile epileptic encephalopathy with 
suppression-burst; XLD, X-linked disorder. 
 
In the past few decades, ion channels predominated in our understanding of the genes 
involved in epilepsy. Recently, evidence has indicated that genes other than those 
encoding ion channels are also related to epilepsy. Examples include TBC1D24 43 , 
STXBP144 and PCDH1945. 
 
Symptomatic epilepsy is usually considered an acquired disorder. However, genetics may 
also play a part in this type of epilepsy. Kanemoto et al found that one polymorphism in 
the promoter of the IL-1β gene (IL1B-511) is significantly associated with hippocampal 
sclerosis in temporal lobe epilepsy. The polymorphism affects IL-1β expression 46 . 
However, it is still difficult to identify genetic factors in symptomatic epilepsy. As stated 
previously, symptomatic epilepsy patients usually receive brain insults such as tumors or 
infections, however, not everyone who suffers such brain insults goes on to develop 
epilepsy, possibly indicating that some people are genetically predisposed to epilepsy 
after such insults. This hypothesis still needs to be further investigated.   
 
1.2.2 Gene expression in epilepsy 
 
The exact mechanism of molecular and cellular factors in seizure disorders remains 
elusive. One of the most fundamental seizure-associated changes in the brain is gene 
expression. It is widely accepted that gene expression can be altered after seizures 
occur47 , 48 . This may hint at genes which play important roles in epilepsy. Examples 
include ion channels, neurotransmitter receptors, and axon growth families 49 , 50 . 
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Nevertheless, gene expression changes can also happen before seizure onset51. This may 
explain why some people are predisposed to develop epilepsy.  
 
Previously, genes were often selected for study based on their previously described 
functions, with methods such as in situ hybridization and real-time PCR being used to 
explore expression48. Later, DNA microarrays made it possible to test the mRNA 
expression of thousands of genes at the same time52. For epilepsy, many of these studies 
concentrated on the hippocampus, which is associated with major forms of epilepsy and 
learning and memory53. For example, one study conducted by Qian et al looked into 
genes dependent on neuronal activities of the hippocampus; a hippocampal cDNA library 
was constructed from rats one hour following seizures, and cDNA probes from normal 
cortex were used to detect genes that were differentially expressed. Five immediate early 
genes were identified54.  
 
Changes in brain mRNA expression may affect cell proliferation, axon guidance, or 
neuronal excitability, which in turn may lead to recurrent seizures. Finding such changes 
would provide us new therapeutic targets to prevent seizures.  
 
However, there are a number of obstacles to identifying these targets. It is difficult to 
illustrate the exact mechanism underlying these changes in mRNA expression. 
Furthermore, it is hard to determine which genes exhibit strong effects on the disease 
among all the genes which showed expression changes. Recently identified molecules 
such as miRNAs can also play a significant role in regulating gene expression55.  
 
Another issue to be considered is the localization of mRNA. Quantification of proteins 
and mRNA is often performed on tissue homogenates, but homogenates contain no 
information regarding cell type or subcellular localization. This will mislead us if the 
expression of a gene is reduced in one cell type but increased in another cell type. To 
address this difficulty, immunohistochemistry can be used, and it can provide valuable 
data on localization. In addition, Crino et al discovered microdissection as another 




1.2.3 Genomics in epilepsy 
 
Genomics refers to the alterations of DNA sequence of different people that may indicate 
different clinical outcome. Synonomous SNPs do not cause sequence changes in amino 
acids, but they may affect protein function or expression through influencing regulation 
of genes, for example, through effects on splicing, mRNA stability, or transcription. 
Nonsynonomous SNPs indicate alterations of amino acids; as a result, the function of the 
protein may be affected. For instance, Vitko et al reported 12 SNPs in the T-type Ca2+ 
channel gene CACNA1H which are related to absence seizures in childhood epilepsy 
patients57. In another study, Buono et al identified an epilepsy susceptibility allele in the 
potassium channel gene KCNJ10 through genetic linkage analysis58. In the “common 
disease- common variants” hypothesis, it is proposed that common variants contribute to 
common diseases. The common variants may not necessarily cause disease but may tag 
causative variants through linkage disequilibrium (LD)59, thus people with risk variants 
are predisposed to develop disease. Different ethnic groups may exhibit different allele 
frequencies of each variant or different LD between variants.  
 
Genomics may also illustrate some phenomenon in symptomatic epilepsy. Not each 
individual will develop epilepsy after brain insults. Thus, such insults alone are not 
sufficient to cause epilepsy, and genetic variation might plausibly influence risk of 
developing symptomatic epilepsy. A particular set of predisposing SNPs plus a certain 
brain lesion may interact together in this type of epilepsy. Some SNPs may become 
biomarkers to predict whether people who receive brain tumor, injury, or stroke are 
predisposed to develop epilepsy, and identify their level of risk as high, moderate, or low.  
In addition, SNPs may also reflect a dosage effect on some drugs. For example, SNPs 
could influence the expression or function of some transporters or enzymes that are 
necessary for drug metabolism or transport60. Although pharmacogenetic study could 
give us instructions on which drug to choose, it can’t reflect the dosage range exactly 




Another genomic trait that is associated with epilepsy is copy number variation (CNV). 
In copy number variants, part of a DNA sequence is duplicated or deleted, leading to 
either extra or fewer than the normal number of copies of the sequence (usually two). 
CNVs can be inherited as a normal trait or caused by de novo mutation. Numerous 
studies have identified deleted or duplicated chromosomal regions that are related with 
epilepsy61- 64. 
  
1.2.4 Animal models 
 
Animal models can give us better insight into the pathophysiology of epilepsy65. Many 
different rodent models have been used to study the cellular mechanisms of 
epileptogenesis, including cell proliferation, cell death, or pharmacological changes in 
cell excitability. The most widely used model is kindling, in which animals are usually 
given repeated treatments of electrical stimulation over a few days to several weeks66- 68. 
Such treatment may eventually lead to convulsive seizures. Therefore, kindling is usually 
considered a model of epileptogenesis because it is clearly progressive and can lead to 
recurrent seizures. However, an important issue is that spontaneous seizures in kindled 
animals are rare except in cases of constant and extreme kindling paradigms for weeks to 
months. Sometimes, kindled animals do not truly develop “epileptic seizures”. The initial 
kindling studies were performed on rats, and later on several other mammalian species, 
such as mice, cats, dogs, and even several varieties of primates69. Other models used 
chemical compounds such as the chemoconvulsants pentylenetetrazole (PTZ), kainate or 
pilocarpine to induce seizures. 
 
Another effective model to study epilepsy uses gene knockout since we already know 
that mutations in ion channel genes (described in 1.2.1) may lead to epilepsy, making 
such a model particularly relevant to human epilepsy syndromes. However, some 
epilepsy syndromes can not be modeled solely based on mutation or knockout of a single 
gene; most cases of human epilepsy seem to be the consequence of interaction of genes. 
In addition, the genetic backgrounds of humans and other animals are quite different, thus 
the same gene may have different genetic patterns, such as SNPs, which may contribute 
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to different phenotypes of epilepsy syndrome. As a result, a gene mutation in mice that 
leads to seizures may have no effect in humans because other differences in gene 
sequence may compensate for the effect of the mutation70.    
 
1.3 Methods to identify variants affecting disease susceptibility  
1.3.1 Traditional methods to identify genetic loci for disease susceptibility 
 
Previously, linkage analysis and candidate gene studies were widely used to discover the 
genetic bases of particular diseases71. However, attempts to find genetic loci for epilepsy 
susceptibility were quite disappointing. Linkage analysis scans genetic markers across the 
whole genome to identify markers that are inherited with a disease gene in families. Due 
to the limited number of disease families, this analysis has low power and low resolution 
to discover genetic risk factors. Another common method is the candidate gene approach, 
in which some loci are first assumed in particular candidate genes based on their 
biological functions, such as ion channel genes in epilepsy, and then variants in the genes 
are genotyped in patients and controls to identify genes with variants that are more or less 
common in patients than in controls. This method will inevitably ignore other genes that 
may be involved in disease. A study conducted by Cavalleri et al examined sporadic 
epilepsy patients for SNPs in candidate genes selected based on biological knowledge72, 
however, no risk factors were found. 
 
1.3.2 Genome wide association study (GWAS)  
 
Genome wide association study (GWAS) is an effective way to find genes that contribute 
to common and complex diseases. It investigates the whole genome and examines 
common variants, usually SNPs, among different individuals to find genetic traits linked 
to a particular disease. Availability of sequencing of the human genome lays the 
foundation of GWAS. Patients and control DNA samples are collected and read in SNP 
arrays. At present, arrays can consist of 1 million or more SNPs, tagging a large fraction 
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of genetic variation by LD73. Such information could be obtained by the International 
Haplotype Map (HapMap) Project, from which LD structures of different ethnic 
populations are available74. 
 
In GWAS, a large sample size is usually required for sufficient statistical power of data 
analysis, thus the high cost of genotyping many subjects becomes an essential problem. 
To overcome this difficulty, multi-stage study designs are often used, in which a subset of 
samples are genotyped in the discovery stage using genome-wide SNP arrays, and then 
the most significant SNPs from stage 1 are genotyped individually in the follow-up stage. 
Data from the first stage and follow-up stage are combined and analyzed. Although the 
cost of SNP arrays is becoming cheaper, making multi-stage design less essential, it is 
still an effective way to reduce the large cost of GWAS.  
 
Usually, some cases with a particular disease and unaffected controls will be selected for 
a so-called case-control study. Cases and controls should be matched for sex, age, and 
ethnicity, and should represent the whole population in which the study is conducted to 
prevent population stratification bias. This bias could be amplified if family members 
rather than unrelated controls are used for genotyping, which would also decrease the 
power of statistical analysis and the possibility to detect association between genetic 
variants and disease. Quality-control checks and testing for Hardy-Weinberg equilibrium 
will be performed to confirm the samples which have been successfully genotyped and 
delete those which fail testing.  
 
In addition, one must address the multiple comparison issue involved in GWAS; one 
simple and effective way is to use Bonferrnoi correction, in which the conventional p 
value (0.05) is divided by the number of independent tests. For genome wide statistical 
significance analysis, SNPs tagging on the order of 1 million independent variants will 
usually be evaluated to calculate the results. Thus there will be 1 million independent 




Normally, odds ratio (OR) is used to represent the effect size. The OR measures the ratio 
of two proportions: the proportion of individuals in the case group with one specific allele, 
and the proportion of individuals in the control group with the same allele. If one allele is 
more frequent in cases than in controls, it is thought to be associated with the disease. 
Nonetheless, association does not necessarily mean causation. Confounders such as 
different ethnicities and genotyping batches could also be associated with a particular 
variant75. 
 
1.3.3 A GWAS of symptomatic epilepsy in the Chinese population   
 
Previously, there was only one GWAS of partial epilepsy. It was performed in 3445 
European patients and 6935 controls, but no significant variant was identified76.  A recent 
GWAS of symptomatic epilepsy in Chinese reported a number of SNPs. The most 
significant SNPs were rs2292096 [G] (p=1.0×10-8, OR=0.63) and rs6660197 [T] 
(p=9.9×10-7, OR=0.69), both on 1q32.1 in the CAMSAP1L1 (also known as CAMSAP2) 
gene77. The former reached genome wide significance. SNP imputation reveals that SNPs 
covering the whole gene are in tight LD (Figure 1.1). This indicated that SNPs are well 
correlated with each other within this gene, and recombination seems to rarely occur 
within the region of this gene, thus the alleles of nearly all SNPs can be predicted if the 




Figure 1.1 LD plot of the CAMSAP1L1 gene. The highlighted region was based on 
HapMap CHB release 22 using the pair-wise correlation coloring scheme of 





Table 1.2 Details of SNPs demonstrating an association with epilepsy at p<0.05 in 
the replication cohort77 
  Discovery cohort Replication cohort Combined 
cohorts 




p value OR 
(95% CI) 
p value* p value 










































rs1980406 DSCAM C 1.77  
(1.32-2.39) 




OR, odds ratio; CI, confidence interval; * one-tailed p-value in the replication stage. 
 
Table 1.2 lists details of the SNPs most significantly associated with epilepsy from the 
discovery and replication cohorts. The findings of this GWAS contradict those of the 
GWAS in the European population. One reason for this discrepancy could be differences 
in phenotypes of epilepsy. In the European study, patients were heterogeneous, having all 
types of partial epilepsy (idiopathic, symptomatic, and cryptogenic), however, the 
discovery phase of the Chinese GWAS only included symptomatic epilepsy patients. It is 
possible that common genetic variants may only contribute to symptomatic epilepsy, but 
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not idiopathic and cryptogenic epilepsy. Another reason could be ethnic differences in 
genetics. The SNPs in Table 1.2 may be tagging SNPs which are in LD with causative 
variants (i.e., variants that change disease risk by directly affecting gene function or 
expression). For a particular gene, causative variants might exist in one ethnic group but 
not another. In addition, LD may differ between ethnic groups, thus associations of 
tagging SNPs with causative variants may occur in one ethnic group but not another.  
Another factor could be that minor alleles were more common in Chinese than in 
Europeans for several of the above SNPs (Table 1.3), giving the Chinese GWAS greater 
statistical power to detect an association of those SNPs with epilepsy. SNP information 
was obtained from the dbSNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/). 
Thus, these conclusions might be unique to the Chinese population. 
 
 
Table 1.3 Minor allele frequencies of GWAS SNPs by ethnicity 
SNP Gene 
Minor allele frequency 
in Chinese 
Minor allele frequency 
in Europeans 
rs2292096 CAMSAP1L1 19% 13% 
rs6660197 CAMSAP1L1 21% 13% 
rs4853352 SNAR-H 19% 43% 
rs2164851 SNAR-H 11% 21% 
rs13021324 ERBB4 31% 16% 
rs2367575 KDM3A 2% 24% 
rs6872795 SPEF2 15% 32% 
rs702416 KCND2 45% 8% 
rs1980406 DSCAM 1% 3% 
 
We decided to further study the two SNPs in CAMSAP1L1 and the SNP in ERBB4 for the 
following reasons. First, CAMSAP1L1 was most strongly associated with epilepsy, and 
little is known about the function of the CAMSAP1L1 protein, thus any light we can shed 
on its function may help in our understanding of epileptogenesis, as well as in the basic 
biological role of this protein. Second, ERBB4 is a gene that encodes ErbB4 protein, 
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which promotes synapse formation of GABA-containing interneurons. It is a 
schizophrenia-susceptibility gene, and it is also involved in epilepsy (discussed in chapter 
1.5). 
 
All the SNPs we aim to study are in non-translated regions, indicating that they will not 
cause changes in amino acid sequence and protein structure. Actually, most of the SNPs 
associated with disease found in GWAS are in intergenic regions, introns or untranslated 
regions rather than in coding regions78,79. Thus there must be other mechanisms involved 
in the association of these SNPs with disease. These SNPs could be in LD with causative 
SNPs, or could affect gene expression through operating at an epigenetic level or 
posttranslational level, such as DNA methylation or chromatin modifications. 
 
1.4 Functions of the CAMSAP family 
CAMSAP1L1 (calmodulin regulated spectrin-associated protein 1-like 1), also known as 
CAMSAP2, encodes a cytoskeletal protein; however, it is not yet known to have any 
neurologically-specific function. The CAMSAP family was first mentioned in drosophila 
by Goshima et al80, and then Baines et al described three homologs belonging to the 
CAMSAP/ssp4 family, CAMSAP1, CAMSAP2 (CAMSAP1L1), and CAMSAP3 81 . 




Figure 1.2 Domain structure of the human CAMSAP family: CAMSAP1, 
CAMSAP2 (CAMSAP1L1) and CAMSAP3. Near the N-termini are CH-like 
domains, and the CKK domains lie in the C-terminal regions. Three coiled-coil 
regions are in the middle. Figure is from Baines et al81. 
 
Proteins of the CAMSAP family have an N-terminal CH (calponin homology) domain, a 
central coiled-coil region, and a CKK (C-terminal microtubule-binding) domain which is 
predicted to bind microtubules. The binding partners of the three domains of CAMSAP 
proteins have been examined by expressing each domain as a separate fragment with a 
tag for easy visualization81. The CKK domain co-localizes with microtubules. The CH 
domain appears diffusely throughout the cytoplasm. The central coiled-coil region is 
localized in small, microtubule-nucleating foci.  
 
In primary cerebellar granule cells, CAMSAP1 and β-tubulin showed a substantial 
overlap in their subcellular distributions. In PC12 cells, the CKK domain may inhibit 
microtubule function by blocking neurite extension. Yamamoto et al described camsap1 
in astrocytic-lineage cells in rats. It was present in all cells containing glial fibrillary 
acidic protein (GFAP) and could be used as a marker for astrocytes. In addition, camsap1 
seems to interact with intermediate filaments (IFs) 82 . Goodwin and Vale identified 
Patronin (ssp4) as an orthologue of CAMSAP family proteins in Drosophila S2 cells83. 
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This protein could stabilize and cap microtubule minus ends and protect them from 
Kinesin 13-induced depolymerization. They proposed that Patronin may serve as a 
scaffolding protein involved in the assembly of microtubules. They also demonstrated 
that members of the Patronin family bind to microtubule minus ends with high selectivity, 
indicating that they must recognize special structures in microtubule minus ends. In the 
polar structure of microtubules, α-tubulin faces the minus end, while β-tubulin faces the 
plus end84. Therefore, it is likely that the CKK domain recognizes special structures at 
the minus end of α-tubulin, but not β-tubulin at plus ends. Fan et al identified one anti-α-
tubulin antibody that could specifically bind to minus ends, suggesting that an epitope 
(the first 100 N-terminal residues) of α-tubulin is only exposed at the minus end of 
microtubules85. Thus, it is likely that the CKK domain can recognize such features of α-
tubulin and regulate microtubule functions via this binding. However, whether this 
interaction exists still needs to be investigated. Depletion of Patronin will lead to free 
movement of microtubules in the cytoplasm through treadmilling. Manna T et al 
described a Stathmin family protein, SCG10, which could destabilize microtubule minus 
ends and provide soluble tubulin to supply extension of microtubule plus ends, thus 
increasing neurite outgrowth86. In contrast, CAMSAP family proteins may function as 
repressors of neurite outgrowth since the CKK domain binds to microtubules and 
stabilizes minus ends. 
 
So far, limited information is known about the gene CAMSAP1L1. Thus, it is still not 
clear what role this gene plays, although we know some information about its family 
member, CAMSAP1. Whether it acts as an important factor in symptomatic epilepsy 
awaits further investigation. A possible relation of CAMSAP1L1 with epilepsy is 
indicated by the fact that overexpression of the CKK domain inhibits neurite extension81. 
As a result, signal transmission may be influenced due to the expression of this gene. 
However, it is still too early to draw any conclusions before we know the exact role of 




1.5 Functions of ErbB4 
The tyrosine kinase receptor ErbB4 (erythroblastic leukemia viral oncogene homolog 4) 
has been widely studied87. ErbB4 is widely expressed in adult and fetal tissues such as 
brain and heart88. It is a member of the ErbB family, which regulates cell proliferation, 
growth, and differentiation. The family consists of four members, ErbB1, ErbB2, ErbB3, 
and ErbB4, which share similar structure and function. However, the gene for each 
member is on a different chromosome89. In general, the mechanism and action of ErbB4 
is similar to that of ErbB1.  
 
ErbB4 has four different isoforms generated by alternative RNA splicing. One isoform 
contains the JM-a exon, which can shed the ErbB ecto-domain upon cleavage by matrix 
metalloprotease TACE (tumor necrosis factor-α-converting enzyme), forming an 80-kDa 
membrane bound protein which contains an intracellular domain90.  
 
Neuregulin-1 (NRG1) is a well-studied ligand, which binds to ErbB4 with high affinity 
and specificity 91 . NRG1-ErbB4 signaling is indispensable for some neurobiological 
processes in the adult brain, such as neurogenesis, synaptic plasticity, migration and 
differentiation of neurons and glia92, and production of GABA-containing interneurons in 
the hippocampus, especially fast-spiking, parvalbumin-positive (FS-PV) interneurons93,94.  
 
Recently, ERBB4 has been identified as a gene involved in the pathophysiology of 
schizophrenia, and SNPs in ERBB4 were found to be associated with schizophrenia95. 
Some antipsychotic drugs are reported to modify the expression of NRG1 and ErbB4; 
these alterations might also affect the pharmacological effect of antipsychotic drugs96.  
 
Backx et al reported one case of early myoclonic encephalopathy with disruption of 
ERBB4, suggesting that this gene may be involved in epilepsy97. Li et al found that 
NRG1-ErbB4 signaling could regulate the excitability of FS-PV interneurons (which are 
down-regulated in epilepsy) and contribute to human epilepsy98. They also showed that 
Pvalb-cre; Erbb4− /−  mice are more susceptible to PTZ- and pilocarpine-induced 
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models of epilepsy, and that exogenous NRG1 could ameliorate seizures. In temporal 
lobe epilepsy, ErbB4 expression is lower in epileptic foci than in brain tissue from 
normal controls.  Thus ErbB4 may become a new target for rational drug design in 
epilepsy. However, currently, there is still no evidence suggesting that ErbB4 is related to 
symptomatic epilepsy or affects the susceptibility of people to develop seizures.  
  
1.6 Hypothesis and proposed plan for expression study of CAMSAP1L1 and ERBB4 
1.6.1 Proposed hypothesis of CAMSAP1L1 and ERBB4 in symptomatic epilepsy 
 
Based on our current knowledge, we proposed a hypothesis that CAMSAP1L1 and 
ERBB4 affect the susceptibility of people to develop symptomatic epilepsy. For the 
CAMSAP1L1 gene, the CKK domain could inhibit neurite extension, thus this gene may 
play a role in neuronal connectivity; for the ERBB4 gene, it is already known that it plays 
a role in regulating the excitatory and inhibitory input balance of inhibitory interneurons. 
Protein expression can be affected by some SNPs, and people with alleles that reduce risk 
of epilepsy (G in rs2292096 and C in rs13021324) have higher or lower expression that 
can counterbalance the detrimental effect which is caused by brain insults. Because these 
SNPs are in non-coding regions, the genetic associations of the SNPs with epilepsy are 
likely due to effects of other variants (tagged by the SNPs) that influence the regulation 
of expression levels of CAMSAP1L1 and ERBB4. 
 
1.6.2 Objectives of the study 
 
1. To determine whether genotypes affect CAMSAP1L1 and ERBB4 expression (RNA 
and protein) in human epilepsy brain samples.  
2. To compare CAMSAP1L1 expression (RNA and protein) between epilepsy and control 
matched tissue (hippocampus and temporal lobe). 





1.6.3 Significance of the study 
 
The current study will be clinically relevant. Once the roles of these genes in epilepsy are 
deciphered, we will have a better understanding of the mechanism of symptomatic 
epilepsy. In addition, new drugs that interact with genes or proteins and regulate gene 
expression or functions could be designed, thus providing new routes for preventing and 
treating symptomatic epilepsy.  
 
1.7 Study scheme 
This study is divided into the following three parts: 
1.  We used real-time PCR and Western blotting to measure mRNA and protein 
expression of CAMSAP1L1 and ERBB4 in hippocampal and temporal lobe samples from 
epilepsy patients, and we compared levels among genotypes of the three SNPs. This 
showed whether genotypes change gene expression. 
2.  Since we were also interested in whether CAMSAP1L1 is expressed differently in 
epilepsy patients compared to controls, we performed immunohistochemistry to semi-
quantify protein expression in matched, formalin-fixed, paraffin-embedded (FFPE) 
hippocampal and temporal lobe tissues from epilepsy patients and post-mortem controls. 
This provided insight into whether gene expression is associated with epilepsy. 
3.  Because few studies of CAMSAP1L1 have been published, we tried to elucidate some 
of its functions. Based on published data regarding its family members, we performed 
double immunofluoresence to observe its localization with tubulin and transfected siRNA 









As mentioned in Chapter One, the hippocampus is often the focus of epileptic seizures. 
Hippocampal sclerosis is the most common type of pathology in temporal lobe epilepsy, 
which is the most common form of epilepsy in adults experiencing poorly-controlled 
seizures. Sclerosis is a good indicator for the outcome of surgery, although we still do not 
know the direction of causation: whether hippocampal damage leads to epilepsy or 
whether recurrent seizures cause hippocampal abnormalities 99 - 101 . Most epilepsy 
surgeries involve temporal lobectomy and hippocampectomy, and some studies use DNA 
microarray analysis to compare the gene expression profile in sclerotic hippocampi102,103. 
The gene expression changes may be connected with genetic background leading to 
epileptogenesis. Investigation of the gene expression profile in hippocampus and 
temporal cortex in epilepsy can help us gain insight into the molecular pathways leading 
to epileptogenesis.  
  
In this chapter, we focus on the expression profile of different SNPs, rather than 
comparing hippocampi with or without sclerosis. Genotyping of SNPs rs2292096 and 
rs13021324 was performed on hippocampus and temporal lobe tissue from epilepsy 
patients, and mRNA levels were compared among different genotypes.  
 
2.2 Materials and methods 
2.2.1 Materials  
 
Fresh brain tissue was collected during surgery on epilepsy patients with hippocampal 
sclerosis (unilateral or bilateral, pathologically confirmed)-related drug-resistant epilepsy 
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who underwent anterior temporal lobectomy and amygdalohippocampectomy at Prince of 
Wales Hospital. Sample sizes were n=26 (hippocampus) and n=22 (temporal lobe). The 
temporal lobe samples were a subset of the 26 samples from hippocampus. The ethics 
committee of the Prince of Wales Hospital approved the study. Trizol reagent was 
purchased from Invitrogen. FastStart Universal Probe Master Mix and Universal Probe 
Library Set were purchased from Roche. DEPC treated water and all the primers were 
ordered from Invitrogen. QuantiTect Reverse Transcription Kit was purchased from 




DNA was purified from blood samples. Genotyping was performed by the tetra-primer 
ARMS PCR method104- 107. The principle was based on tetra-primer PCR and ARMS 
(Amplification refractory mutation system) 108 . Briefly, four primers were needed to 
amplify the template DNA containing two alleles. Two small fragments with different 
sizes represented allele-specific products. Primers were specially designed so that 
amplicons were of different sizes and could be separated by agrose gel electrophoresis. 
Primers were designed by the program BatchPrimer3 software109. Primers for genotyping 




Table 2.1 Genotyping primer information for rs2292096 and rs13021324 














 Forward outer 5’- 
TTAGTTTATTTTCACATTAGGTTCTGGA 
0.1 















 Forward outer 5’- 
GGAAAAACTATAGACCAGCAGGAGAGTA 
0.1 




PCR reactions (total volume 25 μl) contained 100 ng of genomic DNA, 2.5 mM MgCl2, 
10 mM dNTP (2.5 mM each), and 1 U of AmpliTaq DNA polymerase (Applied 
Biosystem) with PCR buffer and the appropriate four of the above listed primers. Cycling 
conditions were 10 min at 95°C followed by 40 cycles of 94°C for 30 s, annealing (at 
58°C for rs2292096 and 57°C for rs13021324) for 30 s and 72°C for 30 s; and a final 
cycle at 72°C for 7 min. PCR products were separated by electrophoresis on 3% agarose 
gels. 
 
2.2.3 RNA extraction 
 
RNA from frozen tissues of epilepsy patients was extracted in order to quantify RNA 
expression of genes. Briefly, first, Trizol reagent was added to sterile fresh tubes, patient 
tissues were cut into small pieces and placed in the tubes, and then tissues were 
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pulverized with an electronic homogenizer. Chloroform was added into the lysate, mixed 
gently and incubated for 3 min at room temperature, and then the tubes were centrifuged 
at 12000×g for 15 min at 4°C. The upper aqueous phase was transferred to another fresh 
tube. Isopropyl alcohol was added to the tube, which was then mixed gently and 
incubated for another 10 min at room temperature. Then the samples were centrifuged at 
14000×g for 10 min at 4°C to precipitate RNA. After pouring off isopropyl alcohol, RNA 
was washed with 75% ethanol, and the pellet was air dried. Finally, RNA was dissolved 
in DEPC water, diluted with DEPC water, and the RNA concentration was measured by 
UV spectrometry at 260 nm and 280 nm (NanoVue, GE Healthcare). Then the RNA 
samples were stored at -80°C.  
 
2.2.4 Reverse transcription PCR  
 
Reverse transcription was performed by using a QuantiTect Reverse Transcription Kit 
(Qiagen) according to the manufacturer’s protocol. Briefly, the RNA samples were mixed 
with RNase free water and gDNA wipeout buffer and incubated for 2 min at 42°C to 
eliminate the genomic DNA. Then the mixture was placed on ice and added to a master 
mix prepared from Quantiscript Reverse Transcriptase, RT buffer and RT primer mix. 
The whole reaction system was incubated for 15 min at 42°C for reverse transcription and 
then incubated for 3 min at 95°C to terminate the reaction. After the reaction, cDNA was 
stored at -80°C. 
 
2.2.5 Real-time PCR 
 
Real-time PCR primers for CAMSAP1L1 and ERBB4 were designed by the Roche online 
tool Universal Probe Library Assay Design Center (Table 2.2). 
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Table 2.2 Real-time PCR primers 
  Gene Access ID Primers Probe # 
1 CAMSAP1L1 NM_203459.1 Forward: CCATCAAGCCTTTTGACCAC 
Reverse: TGAAGTTCCTCTGGCACATTT 
81 









Because ERBB4 has two different mRNA IDs, representing different isoforms, we aim to 
investigate ERBB4 expression of both isoforms, thus a pair of primers that can detect 
both isoforms was designed. GAPDH was chosen as the housekeeping gene to quantify 
RNA expression. 
 
Real-time PCR was performed using the FastStart Universal Probe Master and Universal 
ProbeLibrary Set (Roche) on an ABI 7900HT Real-time PCR machine. The reaction of 
real time PCR included 1x final concentration of FastStart Universal Probe Master 
(ROX), 250 nM UPL probe, 900 nM forward primer (10 µM), 900 nM reverse primer (10 
µM), and cDNA occupying 25% of the total reaction volume.  
The real-time PCR thermal cycling condition was as follows: 
Cycles Analysis Mode Temperature Hold Time Remarks 
1 None 95°C 10 minutes Activation of FastStart 
Taq DNA Polymerase 
40 
None 95°C 15 seconds Denaturation 
Quantification 60°C 1 minute Annealing 
1 None 40°C 2 minutes Cooling 
 
All the patient samples were tested in one batch (26 from hippocampus and 22 from 
temporal lobe) to reduce the difference between different batches. And each sample was 




2.2.6 Data analysis  
 
Genotypes of patient samples were read from the gel bands. In Real-time PCR, the 
conventional ΔΔCT method was used to quantify gene expression110. For each sample, 
mean cycle threshold (Ct) values of the genes CAMSAP1L1, ERBB4 and GAPDH were 
obtained, and relative expression value was calculated by the following equation: 
 
2 GAPDH target geneCt Ctrelative gene expression value −=  
 
RNA expression value was normalized with the housekeeping gene GAPDH, and the 
results were shown as the relative value compared to one sample. For statistical analysis, 
the Shapiro-Wilk test was used to determine that CAMSAP1L1 and ERBB4 expression 
data did not follow a normal distribution. Thus, the Kruskal-Wallis test was used to 
analyze the correlation of RNA expression with three genotypes, while the Mann-
Whitney test was performed if only two genotypes existed. In CAMSAP1L1 RNA 
expression analysis, the Mann-Whitney test was also performed between combined 
genotype groups if such a trend existed: for example, AA+AG and GG.  
 
2.3 Results and discussions 
2.3.1 Genotyping  
      
PCR products were run on agarose gels for genotyping. Figure 2.1 shows genotyping 





A        
 
B   
 
Figure 2.1 Agarose gels of genotypes. Left lane: marker (bp). Other lanes: genotypes 











Table 2.3 Summary of genotyping of rs2292096 and rs13021324 
  
SNP Genotype count 
rs2292096 AA AG GG 
20 6 2 
rs13021324 TT CT CC 







The distribution of genotypes and alleles in all samples was very similar to the data of the 
HapMap project in the CHB (Chinese in Beijing) population (17.8% in our results, and 
19% in HapMap for G allele in rs2292096, 28.5% in our results and 31% in HapMap for 
C allele in rs13021324), thus confirming the accuracy of the genotyping.  
 
2.3.2 Real-time PCR 
 
The expression of two genes in one location (hippocampus or temporal lobe) was 
measured in all patients in one batch, ensuring that conditions of different samples were 





Figure 2.2 Real-time amplification curves for CAMSAP1L1 and ERBB4 in temporal 
lobe. Experiments were performed in triplicate. 
 
All the samples were normalized to one sample, thus results were ratios of each sample to 








Figure 2.3 RNA expression analysis of CAMSAP1L1 according to the genotype of 
rs2292096. Each open circle represents each subject, with the green horizontal line 
indicating the average of each group. A, samples from temporal lobe, p=0.059 
(Kruskal-Wallis test). B, samples from hippocampus, p=0.17 (Kruskal-Wallis test). 
 








Figure 2.4 RNA expression analysis of ERBB4 according to the genotype of 
rs13021324. Each circle represents a subject. Green horizontal lines indicate 
averages. A, samples from hippocampus, p=0.17 (Kruskal-Wallis test). B, samples 
from temporal lobe, p=0.46 (Kruskal-Wallis test). 
 
In correlation analysis of CAMSAP1L1 with rs2292096 (Figure 2.3), subjects with the 
GG genotype appeared to exhibit higher expression than subjects with other genotypes in 
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hippocampus and temporal lobe, thus we performed Mann-Whitney tests to compare 
subjects with the GG genotype with subjects with other two genotypes (AA and AG). In 
temporal lobe (p=0.024) but not hippocampus (p=0.15), expression was significantly 
higher in subjects with the GG genotype. In the GWAS, the OR of rs2292096 [G] was 
0.63. That means that G is a low risk variant compared with the A allele. We may thus 
hypothesize that higher expression of CAMSAP1L1 indicates less risk of epilepsy.  
 
In expression analysis of ErbB4 with rs13021324 in both locations, hippocampus and 
temporal lobe (Figure 2.4), there was a non-significant tendency toward higher 
expression with the C allele than the T allele. According to a recent study conducted by 
Li et al98, downregulation of ErbB4 increased susceptibility to epilepsy. This is consistent 
with our results, in which the lower risk ERBB4 allele from the GWAS (C) exhibited a 
tendency, albeit non-significant, to increase ERBB4 expression. 
 
In addition, we examined gene expression in paired samples from two locations 
(hippocampus and temporal lobe) of each patient. Gene expression differences between 
the two locations did not differ much among patients. We also compared the RNA 
expression ratio of hippocampus to temporal lobe of each individual among different 
genotypes of CAMSAP1L1 and ERBB4. For CAMSAP1L1, the H/T (hippocampus to 
temporal lobe) ratio did not significantly differ among three genotypes (p=0.22, Kruskal-
Wallis test). The median ratios were 1.09 for AA, 0.96 for AG, and 0.49 for GG. For 
ERBB4, the H/T ratio did not significantly differ among three genotypes (p=0.52, 
Kruskal-Wallis test). The median ratios were 1.10 for TT, 0.96 for CT, and 1.28 for CC. 
Thus, expression differences between locations did not differ as a function of genotypes. 
2.4 Conclusion 
All samples were genotyped for rs2292096 and rs13021324, and allele frequencies were 
consistent with HapMap data. In the case of CAMSAP1L1, patients with the GG genotype 
tended towards higher RNA expression, which suggested that people with higher 
expression of CAMSAP1L1 were in the lower risk group for epilepsy. In the case of 




higher expression than did patients with the T allele, which corresponded well with Li’s 
study and the GWAS because C was the low risk allele and because downregulation of 
ERBB4 increased epilepsy susceptibility. If this trend is true, the NRG1-ErbB4 signaling 
pathway could also be involved in symptomatic epilepsy and regulate the excitability of 
inhibitory GABAergic interneurons. 
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Chapter Three Protein expression analysis of rs2292096 and rs13021324 
 
3.1 Introduction 
From the mechanistic perspective, altered mRNA expression usually leads to change of 
protein expression, although this is not universal. Seizure-induced mRNA expression 
may lead to long term protein changes that further give rise to functional alterations in 
network organization, cell proliferation, and cell death. Baines et al raised a CAMSAP1 
antibody in a guinea pig and detected three different bands, full-length protein of 170 
kDa and shorter bands possibly due to splicing, proteolytic degradation or cross-reaction 
with other proteins81. In this chapter, we used two commercial CAMSAP1L1 antibodies 
to explore the full-length band and other bands. In such a way, we will avoid the problem 
of underestimation of protein expression if fragments or proteolytic degradation of 
CAMSAP1L1 existed. 
 
For ErbB4, the alternatively spliced JM-a exon could undergo ecto-shedding by matrix 
metalloprotease TACE, generating an 80 kDa membrane-bound fragment containing the 
intracellular domain (ICD) as described previously111. This fragment is barely detectable 
by western blot in cortex, but is modestly higher in cerebellum 112 . No ecto-domain 
shedding was observed in hippocampal neurons in response to NRG-1113.  
   
In this chapter, we will perform western blotting of CAMSAP1L1 and ErbB4. We will 
measure protein expression in epilepsy patients and correlate expression with the 
genotypes we determined in Chapter Two.    
 





Epilepsy patient samples were the same as described in Chapter 2. Two rabbit polyclonal 
anti–human CAMSAP1L1 antibodies (A301-161A and A302-162A) were purchased 
from Bethyl Laboratories, Inc., rabbit polyclonal antibody against the C terminus of 
ErbB4 (sc283) was obtained from Santa Cruz Biotechnologies, and mouse anti-GAPDH 
antibody (AM4300) was bought from Ambion. Anti-rabbit IgG, HRP-linked antibody 
and anti-mouse IgG, HRP-linked antibody were bought from Cell Signaling. Protein 
Inhibitor Cocktail Set III was purchased from EMD Biosciences, Inc. Bio-Rad DC 
Protein Assay Reagents Package and all supplies and equipment for western blot were 
purchased from Bio-Rad. Immobilon Western Chemiluminescent HRP Substrate and 
PVDF membrane were from Millipore. RIPA extraction buffer was from Sigma Aldrich.   
 
3.2.1 Protein extraction 
 
RIPA buffer was used as lysis buffer to extract protein from patient brain samples. In 
brief, Protein Inhibitor Cocktail Set III stock solution was added to RIPA buffer 
according to the manufacturer’s instruction (dilution ratio of 1:200), human and mouse 
brain tissues were dissected and placed in centrifuge tubes, RIPA buffer with protease 
inhibitor was added to the tissues quickly to prevent protein degradation, and the tissues 
were homogenized with an electric homogenizer for 2 min at 4°C. The suspension was 
centrifuged at 4°C at 12,000 rpm for 20 min, tubes were gently removed from the 
centrifuge and placed on ice, the supernatant was aspirated and placed in a fresh tube, and 
the pellet was discarded. Protein concentration was tested by Bio-Rad DC Protein Assay 
according to the instruction manual. Extracted protein was stored at -80°C. 
 
3.2.3 Western blot 
 
Western blot methods were the same for CAMSAP1L1 and ErbB4. Protein samples (50 
μg) were thawed on ice and SDS sample buffer was added. Samples were boiled for 5 
min and run on a 7.5% acrylamide gel at 50 V as samples passed through the stacking gel 
and 100 V for the separating gel. After electrophoresis, proteins were electrophoretically 
 38
Chapter Three 
transferred from the gel to polyvinylidene difluoride (PVDF) membrane at 100 V for 3 h 
on ice. Then the membrane was blocked by 5% non-fat milk at room temperature for 45 
min, and the membrane was incubated with primary antibody (CAMSAP1L1 A161A or 
A162A at 1:2000 dilution, sc 283 at 1:250 dilution, or GAPDH at 1:10000 dilution in 
TBST) at room temperature for 2 h. Then the membrane was washed by TBST three 
times for 5 min each. Secondary antibody (anti-mouse or anti-rabbit at 1:2000 dilution) 
was added to the membrane and incubated at room temperature for 1 h. The membrane 
was washed by TBST 3 times for 5 min each and then washed by TBS twice at 5 min 
each. Finally, antibody binding was visualized by adding Immobilon Western 
Chemiluminescent HRP Substrate to the membrane. The detection system was 
FlourChem Q imaging (Bioscience). For CAMSAP1L1, two different CAMSAP1L1 
antibodies (we named them A1 and A2), which map to different epitopes, were used to 
stain human and mouse brain samples. Then we explored the CAMSAP1L1 bands by 
comparing the blots obtained using A1 and A2 antibodies. 
 
3.2.4 Western blot for quantification of protein samples 
 
In protein quantification of patient samples, each patient sample was loaded on one lane 
except lanes on the two edges of the gel. Mouse cortex samples were chosen as internal 
standards to normalize differences among different gels. On each gel, two internal 
standards were loaded, each in the same lane position (leftmost and rightmost lanes) in 
order to reduce variation. Appropriate concentration of internal standards was chosen so 
that band intensities were almost the same as the sample bands. Western blot procedure 
was the same as described in 3.2.3, except that before the step of incubation of primary 
antibody, the membrane was cut into two parts at about 100 kDa. The upper part (>100 
kDa) of the membrane was incubated with CAMSAP1L1 or ErbB4 antibody, and the 
lower part was incubated with GAPDH (1:10000) antibody. The membranes were then 
incubated with secondary anti-rabbit or anti-mouse antibody, respectively. At last, the 
bands of target protein and housekeeping gene GAPDH intensities were measured by 
Fluor-ChemQ software, background signal was subtracted, and protein expression value 














For each patient, the protein expression was correlated with the genotype. 
 
3.3 Results and discussion 
3.3.1 CAMSAP1L1 band confirmation 
 
Human CAMSAP1L1 and mouse camsap1l1 protein sequence information were obtained 
from the National Center for Biotechnology Information 
(NCBI, http://www.ncbi.nlm.nih.gov). Figure 3.1 lists the sequence comparison of 
CAMSAP1L1 and camsap1l1, and A1 and A2 antibody information. According to this 
information, and because A1 and A2 antibody are both anti-human, we predict that A1 
can recognize CAMSAP1L1 but not camsap1l1, but A2 antibody can recognize both. 
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Figure 3.1 A1 and A2 antibodies map to different epitopes on human CAMSAP1L1 
and mouse camsap1l1, showing species differences for A1 but not A2. 
 
 
The predicted size of CAMSAP1L1 is 168 kDa. Figure 3.2 shows immunoblots of the 
two antibodies. A2 antibody stained a band of ~170 kDa in mice. A1 antibody could not 
stain the same band in mice but could in humans. Thus, A1 and A2 stain the full-length 
human protein, correlating very well with the sequence information. Bands of lower 
molecular mass could represent non-specific binding with other proteins. However, non-
specific bands will not affect the results of quantification since in protein quantification 












                                                   
CAMSAP1L1 A2 
Figure 3.2 Western blots using the two CAMSAP1L1 antibodies. A: 161A antibody 
staining of (1) Mouse frontal cortex, (2) Human frontal cortex, (3) and (4) Human 
SH-SY5Y cell lysate, (5) Human hippocampus, (6) Mouse hippocampus, (7) Marker, 
(8) Human temporal lobe.  B: 162A antibody staining of (1) Mouse frontal cortex, (2) 
Human frontal cortex, (3) and (4) Human SH-SY5Y cell lysate, (5) Human 
hippocampus, (6) Mouse hippocampus, (7) Human temporal lobe, (8) Marker. 




3.3.2 ErbB4 immunobloting  
 
ErbB4 antibody sc283 has been widely used to analyze expression 114 - 116 . Recently, 
Vullhorst et al pointed out that sc283 has some drawbacks; it cross-reacts with other 
proteins117. Figure 3.3 shows results of our blotting. The pattern is almost the same as the 
one in Vullhorst’s study. In addition to ErbB4 (180 kDa), we also observed non-specific 
bands. We did not find processed ErbB4-ICD (80 kDa), probably due to the low levels in 
hippocampus and temporal cortex. Since we only need to estimate the expression of 
ErbB4, non-specific bands do not influence the results. We quantified the 180 kDa band 




Figure 3.3 sc283 Western blot of (1) Marker (2), (3), (4), (5) Human frontal cortex, 
(6) Human temporal lobe, and (7) Human hippocampus. 
 
 
3.3.2 CAMSAP1L1 and ErbB4 protein expression correlation with SNPs in GWAS 
 
As stated in 3.2.4, to quantify the expression of CAMSAP1L1 and ErbB4, the membrane 
was cut into two parts. Figure 3.4 illustrates this process. The upper part of the membrane 
was incubated with CAMSAP1L1 antibody, and the lower part was incubated with 
GAPDH antibody. Finally, band intensities were measured. ErbB4 protein quantification 
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was performed by the same method (picture not shown). Relative protein expression 
values were calculated by the equation listed in 3.2.4, and then protein expression was 
correlated with genotypes from Chapter 2. Figure 3.5 shows the correlation of 
CAMSAP1L1 protein expression with rs2292096 genotypes. Figure 3.6 shows the 
correlation of ErbB4 protein expression with rs13021324 genotypes. The process was the 
same as for RNA expression analysis.  
  
 
Figure 3.4 CAMSAP1L1 protein quantification by western blot. (1) and (8) Internal 
standard (mouse hippocampus) (3) Marker, (2), (4)-(7) Human temporal lobe 








Figure 3.5 Protein expression analysis of CAMSAP1L1 by A2 antibody according to 
the genotype of rs2292096. Each open circle represents each subject, and green 
horizontal lines indicate average values for each genotype. A, Hippocampus, p=0.48 







Figure 3.6 Protein expression analysis of ErbB4 according to the genotype of 
rs13021324. Each open circle represents each subject, and green horizontal lines 
indicate average values for each genotype. A, Hippocampus, p=0.79 (Kruskal-Wallis 
test). B, Temporal lobe, p=0.089 (Kruskal-Wallis test). 
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None of the protein correlation analyses reached significant p values. In the case of 
CAMSAP1L1 (Figure 3.5), samples with GG genotype did not exhibit significantly 
higher expression compared with the other two genotypes. All three genotypes showed 
almost the same mean value of expression, which contradicted what we found in RNA 
analysis. These inconsistencies may be explained by the following reasons.  
 
First, small sample sizes may contribute to this phenomenon. Only two patients had the 
genotype GG, thus any error related to these two samples could have a big effect on the 
result. In addition, in the genotyping, the total number of patient samples was 28. 
However, since surgeries did not always take both hippocampal and temporal lobe 
samples from each patient, we only had 26 samples of hippocampus and 22 of temporal 
lobe, and this reduced statistical power.  
 
Second, degradation of protein and RNA may have introduced variation and obscured 
expression differences. Sample treatment and storage (some patient samples were kept 
for more than five years) may have affected RNA and protein expression.  
 
Third, samples were not from exactly the same locations in the brain. Normally, only a 
small piece of the hippocampus or temporal lobe was cut during surgery, and it is 
unlikely that all the protein and RNA were evenly distributed in the hippocampus or 
temporal lobe. In addition, the current method could not identify RNA and protein 
expression in a particular cell type, i.e., pyramidal cells or granule cells.  
 
Fourth, western blotting is a semi-quantitative method. Band intensity may vary even in 
the same sample due to numerous factors involved in the experiment, such as transfer 
efficiency, smear in the membrane, and the exposure conditions. Furthermore, unlike 
real-time PCR, each sample was loaded only once, increasing experimental uncertainty. 





We cannot now determine which, if any, of the above factors is primarily responsible for 
the inconsistent results. But small sample size may be important. A large sample size 
could overcome variation due to the other factors. 
 
For ErbB4 protein expression correlation analysis with rs13021324 (Figure 3.6), in either 
hippocampus or temporal lobe we observed no significant difference among genotypes, 
which is similar to the pattern of RNA expression analysis. However, the fact that there 
was only one sample with the CC genotype made statistical analysis difficult. In addition, 
the low expression of ErbB4 in hippocampus in our samples may also contribute to this 
since some bands of ErbB4 in hippocampus were barely detectable, making 
quantification difficult.  
 
3.4 Conclusion 
By comparing the sequence and blot differences between human and mouse, we 
confirmed that CAMSAP1L1 appeared as a band of about 170 kDa on western blots. A1 
and A2 antibody could both detect CAMSAP1L1; however, there were also some non-
specific bands on the blots. The sc283 antibody could stain ErbB4 at 180 kDa. ErbB4-
ICD (80 kDa) was barely detectable in our samples. Protein expression was correlated 
with SNPs in CAMSAP1L1 and ErbB4. Results of protein expression analysis of 
rs2292096 in CAMSAP1L1 did not agree with RNA analysis. Protein expression analysis 
of rs13021324 in ErbB4 revealed no significant difference between patients with 
different genotypes of rs13021324. 
 
Chapter Four 
Chapter Four Immunohistochemistry analysis of CAMSAP1L1 
 
4.1 Introduction 
Only a limited number of genes may be involved in the initiation of seizures. Rakhade et 
al found that there seems to be a common group of altered genes regardless of the 
epilepsy pathology118. It is conceivable that genes we found in GWAS play a role in 
regulating the upstream events in the disease, that is to say, different SNPs in genes may 
affect the susceptibility of a person to develop epilepsy after receiving a brain insult. 
These genes, for instance, ion channel or neurotransmitter receptor subunits, may induce 
downstream effects such as seizure recurrence and cell death pathways. On the other 
hand, seizures may also affect gene expression to some degree, and the mechanism 
underlying this complex cycle is still an unanswered question. In this regard, we hope to 
compare expression between epilepsy and control subjects to get a whole picture of the 
disease-related genes. In Chapters two and three, we investigated the influence of SNPs 
on gene expression. In this chapter, CAMSAP1L1 gene expression in epilepsy and 
control subjects will be compared in formaldehyde fixed-paraffin embedded (FFPE) 
tissue blocks, providing hints on the effects of CAMSAP1L1 on downstream effects in 
epilepsy.  
 
4.2 Materials and methods 
4.2.1 Materials 
 
FFPE tissue blocks were kindly provided by Prof. HK Ng (Department of Anatomical 
and Cellular Pathology, CUHK). Patient blocks were obtained from hippocampal 
sclerosis (unilateral or bilateral)-related drug-resistant epilepsy patients who underwent 
anterior temporal lobectomy and amygdalohippocampectomy at Prince of Wales Hospital 
in Hong Kong. Only those with well sectioned tissues showing the sub-regions of 
hippocampus were selected. Control blocks were post-mortem paraffin-fixed tissues of 
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hippocampus and temporal lobe collected in Prince of Wales Hospital. Control blocks 
were matched in anatomical site to cases. 
  
For immunohistochemistry, Dako EnVision+ System-HRP Labelled Polymer Anti-rabbit 
and normal goat serum were purchased from DAKO. 3, 3’-Diaminobenzidine (DAB) kit 
was purchased from Invitrogen. Phosphate buffered saline (PBS) tablets and Mayer’s 




Immunohistochemistry was performed according to the manufacturer’s protocol (DAKO). 
Briefly, 5 µm sections were cut from blocks by microtome (Leica) and mounted on slides, 
which were deparaffinized in xylene and then rehydrated in a graded series of ethanol in 
water.  
 
Antigen retrieval was performed by a microwave method. Sections were immersed in 
citrate buffer (pH=6.0) and heated in a microwave for 5 min (high power) and then 10 
min (medium power).  
 
Endogenous peroxidase activity was quenched by incubating with 3% H2O2 for 6 min. 
Sections were blocked by 10% normal goat serum for 30 min to prevent non-specific 
binding, then rabbit anti-human CAMSAP1L1 A2 antibody (1:200 dilution) or 10% 
normal goat serum (as negative control) was added to the section and incubated overnight 
at 4°C. On the next day, sections were incubated with goat anti-rabbit IgG (labeled HRP 
polymer anti-rabbit) at room temperature for 45 min. Immunoreactivity was observed by 
incubating with 3,30-diaminobenzidine (DAB) for 4 min.  
 
For counterstaining, sections were immersed in Mayer’s Hematoxylin for 3 min, rinsed 
with ddH2O, dipped in acid alcohol (70% EtOH + 1% HCl; topped up with ddH2O), 
rinsed with ddH2O again, and immersed in Scott’s tap water (3.5 g NaHCO3 + 20 g 




At last, sections were dehydrated in an ascending series of ethanol in water and xylene. 
Slides were mounted with mounting medium and covered with cover slips. 
Immunoreactivity was observed by Zeiss Axioskop 2 plus microscope with AxioCam 
digital camera.  
 
4.2.3 Quantification of FFPE samples by Image Pro-Plus 
 
For quantification of FFPE samples, well-sectioned tissues were selected for 
immunostaining. All the slides including cases and controls in one location were stained 
in one batch in order to reduce variation between batches. Immunoreactivity was 
calculated with an approach modified from previous studies.119- 121 Figure 4.1 illustrates 
the quantification method in hippocampus. The conditions were complex. Since samples 
were from surgery, only parts of hippocampus and temporal lobe were cut. Thus we 
could not exactly find each part of the hippocampus. To reduce potential bias in 
localization, we randomly chose five adjacent photos with the highest expression along 
the features of the hippocampus (CA1, CA3, and dentate gyrus) for quantification, and 
measured the mean value of the photos to represent the total expression in hippocampus. 
In each section, five pictures with the highest expression were used to represent all parts 
of the hippocampus or temporal lobe.  
 
The pictures were analyzed by the software Image Pro-Plus (Media Cybernetics, Silver 
Spring, MD, USA). Constant background intensity was set in every picture so that 
positive labeled targets were only selected if they reached a defined threshold above 
background. Area, density and integrated optical density (IOD=immunoreactive area × 
average optical density) were measured, and IOD was used to estimate the total protein 
expression. Then the Mann-Whitney test was performed in SPSS to compare the control 







Figure 4.1 Process of quantification of immunostaining in hippocampus. Locations 
with highest expression of protein were selected. Boxes represent the pictures taken 
by microscope. Pictures were taken at 25× magnification. 
 
4.3 Results and discussion 
4.3.1 CAMSAP1L1 immunohistochemistry  
 
CAMSAP1L1 A2 antibody was used to stain FFPE samples from epilepsy patient 
hippocampus and temporal lobe. Figure 4.2 shows that CAMSAP1L1 immunoreactivity 
was abundant in hippocampus and temporal lobe, which is consistent with immunoblot 
experiments of hippocampus and temporal lobe tissue. From the localization and shape of 
staining, CAMSAP1L1 was likely to be expressed in pyramidal neurons and astrocytes. 
However, since we did not perform staining together with markers for neurons or 
astrocytes, the evidence is still not enough to identify cell types.  
 
Another issue to be considered is antibody specificity. From the western blot result 
(Figure 3.2), we may notice that except for the bands of CAMSAP1L1 at 170 kDa, A1 
and A2 polyclonal antibody both stained some non-specific bands, indicating that these 
two antibodies were not specific to CAMSAP1L1, although they could recognize 
epitopes of CAMSAP1L1. Thus it is possible that in immunohistochemistry, false-
positive staining would occur. 
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A              B 
   
C               D 





Figure 4.2 CAMSAP1L1 immunoreactivity (brown) in A, temporal lobe of epilepsy; 
B, hippocampus of epilepsy; C, temporal lobe of control; D, hippocampus of control. 
E, negative control staining. Arrowheads mark positions of stained cells. Pictures 




4.3.2 CAMSAP1L1 protein quantification between epilepsy and control groups 
 
After staining, samples from hippocampus were screened; sections with no obvious 
features of the hippocampus were dropped from the analysis. The result of semi-




                          A 
 
 
                          B 
 
Figure 4.3 CAMSAP1L1 log10 IOD determined by Image Pro-Plus according to the 
staining percentage by visual assessment. A, Hippocampus (epilepsy n=5, control 
n=9), p=0.059 (Mann-Whitney test). B, Temporal lobe (epilepsy n=5, control n=5), 
p=0.12 (Mann-Whitney test).  
 
According to Figure 4.3A, in hippocampus, expression (log10 IOD) of CAMSAP1L1 
tended to be lower in epilepsy patients than in controls. The p value (0.059) almost 
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reached significance. This is consistent with RNA expression correlation analysis and 
GWAS in that higher CAMSAP1L1 may indicate less risk of epilepsy. On the contrary, 
in temporal lobe, the situation was reversed, but the p value (0.12) was somewhat higher 
than in hippocampus.  
 
One possible explanation of this inconsistency in hippocampus and temporal lobe was 
that all the epilepsy samples were human samples from surgery, thus it is impossible to 
expect that all the patient samples were from the same location in the hippocampus. That 
is to say, different sections of hippocampus were cut from each individual, for instance, 
the tail of the right hippocampus or the head of the left hippocampus.  
 
Conditions were almost the same in the temporal lobe. Surgeries included right anterior 
temporal lobe, left anterior temporal lobe or anterior temporal lobectomy. The current 
study could only focus on one region of the temporal lobe, and used this to represent 
expression throughout the whole temporal lobe. This may cause some bias in 
quantification.  
 
Another factor that may contribute to this inconformity is small sample size (epilepsy 
n=5, control n=5) in temporal lobe. Thus it is still hard to have an accurate conclusion 
about whether expression of CAMSAP1L1 differs between epilepsy and control tissue. 
 
Third, epilepsy and control samples were not perfectly matched, with control samples 
being from post-mortem tissue but epilepsy samples from surgeries on living patients. In 
control samples, post-mortem delay and storage temperature may contribute to protein 
modifications122. Frozen tissue samples may be better for studying protein expression, 
however, since only FFPE samples could be found in matched tissues in epilepsy and 







In sum, immunohistochemistry of sections in hippocampus and temporal lobe showed 
moderate labeling of CAMSAP1L1 protein. Expression of CAMSAP1L1 in hippocampus 
tended to be lower in epilepsy patients than control subjects (p=0.059), consistent with 
our hypothesis and observation from RNA expression analysis of rs2292096 that people 
with lower expression of CAMSAP1L1 have a greater risk of developing epilepsy. But in 
temporal lobe, we did not observe significant difference between the epilepsy and control 
groups.  
Chapter Five 
Chapter Five Double immunofluorescence and CAMSAP1L1 siRNA 
transfection in SH-SY5Y cells 
 
5.1 Introduction 
Epilepsy is a complex neurological disorder, so it is necessary to choose proper neuronal 
cell lines for studying the roles of epilepsy genes in epilepsy. In this study, we chose 
human SH-SY5Y as a cell line to perform our study. Human neuroblastoma SH-SY5Y is 
a dopaminergic neuronal cell line that is a good model system to study neuronal 
properties such as neurogenesis123- 126. SH-SY5Y cells are usually treated with all-trans-
retinoic acid (RA) to differentiate them and obtain properties that are related with 
neurons, such as neurite outgrowth and morphological alterations127. RA can increase the 
survival signaling in SH-SY5Y cells and reduce cellular susceptibility to 
neurotoxins128 , 129 . However, undifferentiated SH-SY5Y cells are also widely used in 
neuroscience research130- 132. One report has demonstrated that neuronal properties may 
greatly differ between differentiated and undifferentiated cells133. Regarding this issue, 
we used both undifferentiated and RA-differentiated cells to study the effect of 
CAMSAP1L1 siRNA transfection on neurite outgrowth to get more understanding of 
CAMSAP1L1 function.  
 
Neurite outgrowth is extremely important in embryonic development, neuronal 
differentiation, and nervous system function. Neurite outgrowth is also critical in 
neuropathological disorders, neuronal injury, and regeneration. The extracellular 
environment and pharmacological agents could affect neurite parameters, including 
length and number of neurites. A previous study had found that overexpression of the 
CKK domain of CAMSAP1 could inhibit axon extension81. Here we determined to knock 
down the whole CAMSAP1L1 protein to see whether this could also display a big effect 




Small interfering RNA (siRNA), also known as short interfering RNA or silencing RNA, 
is a double stranded RNA molecules 20-25 nucleotides long. It is involved in the RNA 
interference (RNAi) pathway and interferes with expression of a specific gene. Briefly, 
such molecules are incorporated into the pre-RISC (RNA Induced Silencing Complex), 
then the passenger strand is released and the guide strand containing RISC is formed. The 
guide strand guides RISC to the complementary region of the target mRNA; such a 
process induces mRNA degradation134. Exogenous siRNA can be artificially introduced 
to cells by transfection to bring about silencing of the specific gene of interest. As a result, 
transfection of siRNA has becoming an indispensable tool for gene function study and 
drug target validation studies in the post-genomic era. However, in dividing cells, gene 
silencing caused by siRNA is only transient; some modifications could be made to 
improve the duration of gene silencing, such as shRNA (short hairpin RNA)135. 
 
In this chapter, we knocked down CAMSAP1L1 expression in SH-SY5Y cells by siRNA 
transfection to study the role of CAMSAP1L1 in SH-SY5Y cells, mainly on neurite 
outgrowth. Because a previous study had found that the CKK domain of CAMSAP1 
could bind to microtubules81, we also performed double immunofluorescence 
experiments to explore the localization of CAMSAP1L1 with tubulin.  
 
5.2 Materials and methods 
5.2.1 Materials 
 
Dulbecco's Modified Eagle Medium (DMEM), and fetal bovine serum (FBS) were from 
Gibco (Grand Island, NY, USA). Glycine, Lipofectamine 2000, Opti-MEM I Reduced 
Serum Medium, and Penicillin-Streptomycin solution were purchased from Invitrogen. 
Rabbit polyclonal β-tubulin antibody (sc9104) was purchased from Santa Cruz 
Technologies. CAMSAP1L1 and negative control Silencer® Select Pre-designed, 
Validated, and Custom Designed siRNA were purchased from Ambion. Mouse 
monoclonal anti-β-tubulin antibody Tub2.1 (T4026), retinoic acid (RA), Bovine Serum 
Albumin (BSA), 3-(4, 5)-dimethylthiahiazo (-z-y1)-3, 5-di- phenytetrazoliumromide 
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(MTT), and PBS tablets were supplied by Sigma Aldich. 4'-6-Diamidino-2-phenylindole 
(DAPI) was kindly provided by Mr.Yong Shang (The Chinese University of Hong Kong, 
Hong Kong). Alexa Fluor 488 goat anti-mouse IgG and Alexa Fluor 568 goat anti-rabbit 
IgG were purchased from Invitrogen. SH-SY5Y cells were kindly supplied by Prof. Mary 
Waye (The Chinese University of Hong Kong, Hong Kong). All other reagents were 
analytical grade. 
 
5.2.2 Double immunofluorescence 
 
Cover slips were autoclaved and placed within 6-well plates. Cells were seeded on cover 
slips at a density of 2×105 per well for 24 h. To start staining, cells were first fixed with 
4% formalin in PBS at room temperature for 15 min. After washing by ice-cold PBS 
twice; the slips were taken out from plates and blocked by 1% BSA in PBS at room 
temperature for 30 min. Then a mixture of diluted primary antibody, rabbit anti-human 
CAMSAP1L1 A1 (dilution 1:200) and mouse anti-β-tubulin (dilution 1:100) in PBS with 
0.5% BSA, was added and incubated at 4°C overnight. The next day, cells were rinsed 
with ice-cold PBS twice and incubated with a mixture of two secondary antibodies, Alexa 
Fluor 488 goat anti-mouse IgG (1:300 dilution) and Alexa Fluor 568 goat anti-rabbit IgG 
(1:300 dilution) in PBS with 0.5% BSA at room temperature for 1 h in the dark. Finally, 
cells were washed by ice-cold PBS twice, and slides were mounted with mounting 
medium glycerol. Cells were photographed using a laser-scanning confocal microscope 
(LSM700 mounted on an AxioObserver Z1 Inverted Microscope, Carl Zeiss 
MicroImaging). 
 
5.2.3 CAMSAP1L1 siRNA transfection 
 
Transfection was performed in 6, 24 or 96 well plates based on different targets of the 
transfection experiments according to the manufacturer’s instructions (Ambion). Table 
5.1 lists transfection conditions for different reagents in different culture plates. 
Lipofectamine 2000 was used as transfection reagent. One day before transfection, an 
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appropriate number of cells (Table 5.1) were seeded on the plates in DMEM without 
antibiotics so that cells would become 30-50% confluent at the time of transfection. For 
each transfection sample, Lipofectamine 2000- siRNA complexes were prepared as 
follows (24 well plates as example):   
a. Diluted 1 μl siRNA (2.5 pmol/μL) in 50 μl Opti-MEM medium, mixed gently. 
b. Diluted 0.7 μl Lipofectamine 2000 in 50 μl Opti-MEM, mixed gently. 
c. After 5 min incubation at room temperature, the two diluted solutions in a and b were 
combined (total volume 100 μl) and incubated for another 20 min for the formation of 
Lipofectamine 2000-siRNA complexes.  
100 μl of Lipofectamine 2000-siRNA complexes was added to each well and mixed 
gently. The plates were rocked back and forth. Then the cells were incubated at 37°C in 
5% CO2. 24 hours later, growth medium was replaced with normal DMEM medium, and 
different procedures were performed in different experiments.  
 
Table 5.1 Transfection conditions in different culture plates 




Cells / well Total volume 
/well (μl) 
96 well 0.1 0.5 10000 200 
24 well 0.7 2.5 20000 500 
6 well 2 12.5 200000 2000 
 
5.2.4 Gene knockdown assay 
 
Transfection was performed on 6-well plates. After transfection, cells were harvested at 
24 h, 48 h, and 72 h for knockdown assay. For the extraction of protein from cells, cells 
were washed by ice-cold PBS twice, then PBS was drained, and ice-cold RIPA buffer 
with protease inhibitors was added to the cells. Cells were scraped from the dishes by a 
cold plastic cell scraper. The cell suspension was transferred to a pre-cooled centrifuge 
tube maintained on ice. Cells were agitated in RIPA buffer every 3-4 minutes, and after 
30 min, tubes were centrifuged at 20000×g for 20 min at 4°C, then gently placed on ice. 
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Supernatants were saved, and the cell pellets were discarded. Protein concentration was 
tested by Bio-Rad DC Protein Assay according to the manufacturer’s instructions. BSA 
was used as a standard. The western blotting procedure was the same as the one described 
in 3.2.3. GAPDH was used as a housekeeping gene. An equal amount of protein (50 μg) 
of each sample was loaded on each lane of the gel. CAMSAP1L1 band intensity was 
measured by a Fluor-Chem system (Bioscience). Knockdown efficiency was analyzed by 
comparing cells transfected with negative control siRNA or CAMSAP1L1 siRNA.  
 
5.2.4 MTT cell viability assay 
 
Cell viability was tested by MTT assay at 48 h, 72 h, and 96 h after transfection in 96 
well plates as described previously, with slight modification136. Cells transfected with 
negative control siRNA were used as controls. For each transfection condition, 10 wells 
were used to evaluate cell viability. MTT was prepared in 5 mg/ml stock solution in PBS. 
24 h after transfection, medium was replaced with normal DMEM medium. Cell viability 
was tested at 48 h, 72 h, and 96 h. For MTT assay, cells were first washed by PBS twice, 
then 20 μl MTT stock solutions dissolved in 150 l PBS was added into each well, the 
solution in wells was mixed gently, and plates were incubated at 37°C in 5% CO2 for 4 h. 
After that, MTT solution was drained, 200 μl DMSO was added into each well, and the 
absorbance in each well was recorded at a wavelength of 570 nm on a microplate reader 
(Benchmark, BioRad, USA). The difference between the negative siRNA group and 
CAMSAP1L1 siRNA group was calculated by Student’s t test, with p<0.05 considered 
significant.  
 
5.2.5 Neurite outgrowth assay  
 
Before the neurite outgrowth assay, SH-SY5Y cells were first differentiated with 25 μM 
RA in DMEM medium.137 One day later, differentiated and undifferentiated cells were 




The neurite outgrowth assay was performed as described previously, with slight 
modifications137. Briefly, cells were seeded on 24 well plates at a density of 20000 per 
well, and then transfected with negative control siRNA or CAMSAP1L1 siRNA 
(described in 5.2.3). One day after transfection, medium was replaced with normal 
DMEM medium with 0 μM or 25 μM RA. For each group, the experiment was performed 
in triplicate. Neurite outgrowth was quantified 36 h after RA treatment. First, cells were 
fixed with 4% formalin in PBS at room temperature for 30 min in 24 well plates. Cells 
were then washed with PBS 3 times, and 500 μl 0.1% Triton X-100 in PBS with 1% BSA 
was added into each well. After incubation for 15 min, the solution was removed, then 
400 μl diluted primary antibody, rabbit anti-β-tubulin antibody 1:50 in PBS with 1% BSA, 
was added per well and incubated for 2 h at room temperature. After that, primary 
antibody solution was removed, and cells were washed with PBS 3 times, then 
fluorescently labeled secondary antibody, goat anti-rabbit IgG Alexa Fluor 568 diluted 
1:300 in PBS containing 1% BSA, was added and incubated in the dark at room 
temperature for 1 h. The cells were washed with PBS 3 times. Finally, 400 μl DAPI 1× 
solution (300 nM) was added into each well for nuclear staining for 15 min in the dark. 
Then 24-well plates were protected from light with tin foil and observed using a Nikon 
inverted Ti-E microscope (Nikon). Red (TRITC) and blue (DAPI) fluorescent signals 
were captured for neurite outgrowth quantification. In total, 4 pictures containing an 
appropriate amount of cells were taken for each well. Metamorph software was used to 
quantify neurite outgrowth, mean cell outgrowth, mean cell processes, mean cell 
branches, and mean cell body area. The above values for the CAMSAP1L1 siRNA group 
were compared with those in the control siRNA group for 0 μM or 25 μM RA treated 
SH-SY5Y cells. Significance was calculated by Student’s t test, with p<0.05 considered 
significant.     
 




5.3.1 Double immunofluorescence  
 
To examine the localization of CAMSAP1L1 in SH-SY5Y cells, we performed double 
immunofluorescent staining for β-tubulin because previous research had demonstrated 
that the CKK domain co-localized with microtubules81,83. From Figure 5.1, we could see 
that CAMSAP1L1 also showed partial but not complete localization with microtubules, 
perhaps because only the CKK domain of the CAMSAP family binds to the minus end of 
microtubules, but not other domains (CH domain and central CC domain). Thus, 
CAMSAP1L1 may function together with other CAMSAP family members and regulate 
microtubule minus end activity138.  
 
 
Figure 5.1 Localization of CAMSAP1L1 and β-tubulin in SH-SY5Y cells. Green (β-
tubulin) and red (CAMSAP1L1 A2) partially overlapped.  
 
5.3.2 CAMSAP1L1 knockdown assay by western blot 
 
Figure 5.2 and Figure 5.3 reveal the extent of CAMSAP1L1 knockdown at different time 
points. CAMSAP1L1 siRNA transfection of SH-SY5Y cells reduced CAMSAP1L1 
 64
Chapter Five 
protein nearly 60% between 48 h and 72 h. At 24 h, almost no change was observed in 
CAMSAP1L1 protein expression compared with the control group, indicating that cells 
need time to carry out the siRNA knockdown process. At 72 h, the knockdown efficiency 
was lower than that at 48h. This may be explained by the fact that our siRNA could only 
lead to transient knockdown, and cells may recover from the siRNA knockdown effect 
after some time. Usually, transient knockdown may only last for a few days; as a 
consequence, it is better to observe cell morphology changes or cell viability caused by 
siRNA transfection at a time point between 48 h and 72 h.        
  
Figure 5.2 Effect of CAMSAP1L1 siRNA on SH-SY5Y cells at different time points. 
(1) Normal SH-SY5Y cells, (2) Negative control siRNA transfection at 24 h (3) 
CAMSAP1L1 siRNA transfection at 24 h, (4) CAMSAP1L1 siRNA transfection at 48 




Figure 5.3 Knockdown of CAMSAP1L1 as measured by ratio of CAMSAP1L1 to 
GAPDH band intensities on western blots of siRNA transfected SH-SY5Y cells. 
Ratio for control siRNA was set at 1. Protein expression in CAMSAP1L1 siRNA 
transfection group was compared with that in control group. Values showed as 
means ± SD of 3 wells.﹡p<0.05 
 
5.3.3 MTT cell viability assay 
 
In the MTT assay (Figure 5.4), OD values represented metabolic activity and thus cell 
survival of each group were calculated according to the following formula: (Mean of the 
transfection group OD – mean of the blank OD). For each day, values were normalized to 
those of the negative control siRNA group. Knockdown of CAMSAP1L1 did not 





Figure 5.4 SH-SY5Y cell viability at 48 h, 72 h, and 96 h after transfection. Each bar 
represents the mean ± SD of ten wells and is normalized to the negative controls for 
that time point.  
 
5.3.4 Neurite outgrowth  
 
25 μM RA in DMEM was used to differentiate SH-SY5Y cells because this 
concentration was enough for differentiation but not toxic for cell viability139. Neurite 
extension and branches could be observed one day later (Figure 5.5), thus confirming that 
RA stimulated development of neurite-like processes. So 25 μM RA was used for the 
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Figure 5.5 Image of undifferentiated SH-SY5Y cells (left) and RA (25 μM) 
differentiated SH-SY5Y cells (right) taken by A, camera directly from ocular of 
microscope (40x magnification) and B, Nikon phase microscope (50× magnification). 
Scale bar equals 100 μm. 
 
In the neurite outgrowth assay, red fluorescent signal (tubulin) and blue fluorescent signal 
(DAPI) were captured by microscope (Figure 5.6). Figure 5.7 demonstrated the process 
of analyzing neurite outgrowth. After adjusting the proper parameters in the Neurite 




         
Figure 5.6 Fluorescent micrographs of tubulin (left) and nuclei (DAPI staining, right) 
(50× magnification). Scale bars equal 100 μm. 
 
 
Figure 5.7 Image displayed by MetaMorph software Neurite Outgrowth Application 
Module. Cell bodies and neurites were automatically detected (red). 
  
Neurite outgrowth quantification was performed at 60 h after transfection since 
knockdown efficiency was probably highest before 72 h (Figure 5.3). Figure 5.8 reveals 
the results of neurite outgrowth quantification. CAMSAP1L1 knockdown significantly 
increased neurite outgrowth, branches, and processes. The results were the same for cells 
incubated with or without RA (except for processes without RA, in which case p=0.06).  
 
The neurite effect may be specific because CAMSAP1L1 knockdown did not change the 
cell body area, at least in undifferentiated cells. Knockdown did increase cell body area in 
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differentiated cells, but RA induced the formation of cell clusters and overlapping 
neurites that sometimes appeared to the software as part of cell bodies.  
 
In sum, we had reason to believe that siRNA inhibition of CAMSAP1L1 expression 
induced neurite outgrowth. This is consistent with a previous study which demonstrated 
that overexpression of the CKK domain inhibited neurite extension in PC12 cells81. All 
three members of the CAMSAP family have a CKK domain, thus it is possible that it is 
the CKK domain which exhibits a repressing effect on neurite outgrowth. But it is still 
unknown which member of the CAMSAP family has more effect on neurites. In addition, 
the method we used was different from the Baine’s study, in which different enhanced 
green fluorescent protein (EGFP)-tagged constructs (EGFP alone, EGFP-central, and 
EGFP-CKK) were transfected into PC12 cells, and the proportions of EGFP-positive 
cells producing neurites were scored140. Although this method could accurately tell which 
cell was transfected successfully, but they did not measure the actual neurite lengths, but 
our studies could quantify neurite length, branches and processes. However, we could not 
choose to analyze only the cells that had been successfully transfected since we did not 





Figure 5.8 Quantification of neurite outgrowth, processes, branches, and body area 
per SH-SY5Y cell treated with 0 or 25 μM RA for 36 h. Data are shown as mean±SD 
of 12 replicates. *p<0.05.  
 
In sum, our neurite outgrowth assay revealed CAMSAP1L1 as a possible repressor of 
neurite outgrowth. Based on this theory, we hypothesized that the allele that increases 
epilepsy risk exerted its effect by decreasing CAMSAP1L1 expression, thus increasing 
neurite extension, leading to stronger neural circuits and a propensity to develop seizures. 
This was also consistent with the CAMSAP1L1 RNA expression correlation analysis with 
SNPs in that higher expression in subjects with the GG genotype corresponded with less 
risk of epilepsy. Since even partial (about 60%) knockdown of CAMSAP1L1 exhibited a 
significant effect on neurite extension, CAMSAP1L1 may play an essential role in the 
extension of neurites. However, further investigation is still needed to decipher whether 




of the CAMSAP family have the same effects on neurite extension as CAMSAP1L1, and 
whether the CKK domain is the key factor influencing neurite extension.   
 
5.4 Conclusion 
Our study demonstrated that in SH-SY5Y cells, CAMSAP1L1 showed partial 
localization with microtubules, probably due to the fact that the CKK domain of 
CAMSAP1L1 binds to microtubules. Knockdown of CAMSAP1L1 by about 60% did not 
significantly affect cell viability but did stimulate neurite growth, in both undifferentiated 
and differentiatied SH-SY5Y cells. As a result, CAMSAP1L1 could be considered a 
cellular repressor of neurite outgrowth. Based on the GWAS and on our study of RNA 
expression, we may hypothesize that inhibition of CAMSAP1L1 expression may lead to 
stonger neural circuits, thus leading to epilepsy.   
Chapter Six 
Chapter Six Overall conclusion and prospects 
 
6.1 Overall conclusion 
6.1.1 CAMSAP1L1 
 
Recently, a GWAS identified variants in CAMSAP1L1 associated with susceptibility for 
symptomatic epilepsy in the Chinese population. However, relatively little was known 
about this gene. We used real-time PCR, western blotting, and immunohistochemistry to 
study CAMSAP1L1 expression and explore whether expression differs among different 
genotypes and whether it differs between epilepsy and control subjects. Furthermore, by 
immunofluorescent staining and siRNA transfection of SH-SY5Y cells, we also explored 
CAMSAP1L1 localization and functions. This is the first study of the expression and 
function of CAMSAP1L1. 
  
The rs2292096 GG genotype tended to show higher RNA but not protein expression (by 
western blotting) than the other two genotypes. By immunohistochemistry, hippocampal 
expression of CAMSAP1L1 tended to be higher in epilepsy than in control subjects, but 
not in the temporal lobe. These inconsistencies between western blotting and 
immunohistochemistry might partially be explained by problems with samples or 
methods, as discussed before. CAMSAP1L1 partially co-localized with β-tubulin. 
CAMSAP1L1 knockdown significantly enhanced neurite outgrowth, cell processes and 
cell branches, but did not affect cell viability.  
 
Based on the results above and the results of the GWAS, we hypothesize that the GG 
genotype of rs2292096 is associated with increased expression of CAMSAP1L1, 
repressing neurite outgrowth, and thus inhibiting epileptogenesis. The effect of 
rs2292096 on CAMSAP1L1 expression may be higher in the Chinese than in the 
European population since the GWAS of Chinese but not the GWAS of Europeans found 
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an association of CAMSAP1L1 with epilepsy. It is possible that a SNP which is in LD 




ErbB4 was previously widely studied for its function and also its potential role in 
epilepsy. We examined the effect of rs13021324 on ERBB4 expression. Both RNA and 
protein analysis revealed no significant difference among three genotypes, In particular, 
RNA expression tended to be more abundant in patients with than without the C allele, 
correlating well with the GWAS and Li’s study in that the C allele decreases risk of 
epilepsy and that ErbB4 is downregulated in epilepsy98. However, the difference of 
expression between genotypes was not significant, thus the associations are not reliable, 
and we cannot yet conclude whether ErbB4 plays an essential role  in symptomatic 
epilepsy.  
  
6.2 Future work  
One drawback of the current study is the small sample size. Thus larger sample sizes are 
needed to achieve sufficient statistical power for reliable results. To calculate the sample 
size needed, we used the online software G*Power (http://www.psycho.uni-
duesseldorf.de/abteilungen/aap/gpower3/download-and-register). We used the observed 
frequencies of subjects possessing at least one G allele in rs2292096 or at least one C 
allele in rs13021324. To obtain 80% power to detect the 50% difference between G- and 
G+ genotypes that we observed in CAMSAP1L1 RNA in temporal lobe, we would need 
24 subjects, only a little bigger than our current sample sizes. To obtain 80% power to 
detect the 20% difference between C- and C+ genotypes that we observed in ERBB4 
RNA in hippocampus, we would need 134 subjects. To obtain 80% power to detect other 
differences than those described above would require a larger number of subjects since 




For the gene CAMSAP1L1, we examined rs2292096 through a SNP function prediction 
website (http://manticore.niehs.nih.gov/cgi-bin/snpinfo/snpfunc.cgi) to try to identify a 
SNP in linkage disequilibrium that may cause a change in expression. We found a SNP, 
rs12733378, which is in perfect LD with rs2292096 and which alters potential microRNA 
binding in the 3’ untranslated region. Four microRNAs, hsa-miR-1257, hsa-miR-1262, 
hsa-miR-200c, and hsa-miR-369-3p, were predicted to possibly bind with different 
affinity to the two alleles of rs12733378. Experiments could be performed to investigate 
whether specific microRNAs could bind to the rs12733378 region and thus affect 
CAMSAP1L1 expression. 
 
Animal models such as kindling are a choice to study gene expression since we can take 
samples from exactly the same brain loci or whole brains of different individuals so that 
we can compare gene expression between epilepsy and controls more exactly. This will 
avoid difficulties we meet in human samples, which are either post-mortem or from 
surgery. However, animal models may not be suitable for expression study of SNPs due 
to differences of genetic background.  
 
Gene knockout mice or siRNA injection can be used to study the function of 
CAMSAP1L1. Epilepsy can be induced in such mice using established animal models 
such as kindling to investigate how CAMSAP1L1 affects the propensity for the animals 
to develop epilepsy. This will help us get a better insight of the role of this gene in 
epilepsy. 
 
Another direction of the study includes screening for drugs to increase CAMSAP1L1 
expression. Such work may be clinically relevant since it may help people with the risk 
allele to prevent seizure occurence if our hypothesis is true. 
 
6.3 Prospects  
The current study helped us get a better insight of the genes found in the GWAS. Some 




symptomatic epilepsy, and the mechanisms underlying epilepsy can be understood better 
once all or most of the pivotal genes involved in epilepsy are decoded. Thus, some 
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